AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD 0.0050
0.00 (0.00%)
Jan 30, 2026, 3:45 PM AEST
AdAlta Revenue
In the fiscal year ending June 30, 2025, AdAlta had annual revenue of 677.01K AUD, down -61.04%. AdAlta had revenue of 301.92K in the half year ending June 30, 2025, a decrease of -87.21%.
Revenue
677.01K
Revenue Growth
-61.04%
P/S Ratio
16.95
Revenue / Employee
677.01K
Employees
1
Market Cap
11.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 677.01K | -1.06M | -61.04% |
| Jun 30, 2024 | 1.74M | -1.73M | -49.91% |
| Jun 30, 2023 | 3.47M | 715.56K | 25.99% |
| Jun 30, 2022 | 2.75M | -1.23M | -30.89% |
| Jun 30, 2021 | 3.98M | 156.64K | 4.09% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 12.68M |
| Immuron | 7.29M |
| Noxopharm | 2.82M |
| Tissue Repair | 2.63M |
| Neurotech International | 2.44M |
| Biotron | 1.81M |
| Patrys | 828.54K |
| Bio-Gene Technology | 524.37K |